Table 2.
The Los Angeles classification and Lanza scores at baseline and after treatment
| Baseline | Post-treatment | p value1 | |
|---|---|---|---|
| Irsogladine group |
|
|
|
| Los Angeles classification |
Grade O (16/16) |
Grade O (16/16) |
|
| Lanza scores (stomach) (mean ± SD) |
0.5 ± 1.1 |
0.9 ± 1.0 |
NS |
| Lanza scores (duodenum) (mean ± SD) |
0.0 ± 0.0 |
0.4 ± 0.9 |
NS |
| Omeprazole group |
|
|
NS |
| Los Angeles classification |
Grade O (16/16) |
Grade O (16/16) |
|
| Lanza scores (stomach) (mean ± SD) |
0.6 ± 0.9 |
1.5 ± 1.1 |
NS |
| Lanza scores (duodenum) (mean ± SD) | 0.0 ± 0.0 | 0.4 ± 0.8 | 0.0049 |
1P-values are baseline versus post-treatment within groups.